ArticleNature2019
TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection.
Article in Nature, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03941496 (Phase 1b/2a Safety and Immunogenicity of the DNMT Inhibitor Azacitidine During Anti-Tuberculosis Therapy), which is not on this map. Cited by 598 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase 1b/2a Safety and Immunogenicity of the DNMT Inhibitor Azacitidine During Anti-Tuberculosis Therapy
Who cites it
598 citing papers in PubMed, 855 citations in OpenAlex.
- Inhibitory receptor profiles for joint prediction of benefit and toxicity in immune checkpoint blockade.iScience · 2026Review
- LAG3 checkpoint function and its mechanism of action in therapeutic targeting.Nature reviews. Immunology · 2026Review
- CD39 on CD8European journal of immunology · 2026Review
- ANKRD11 deficiency reprograms CD8Nature immunology · 2026Article
- A T-cell exhaustion-related signature for predicting response to immunotherapy among patients with lung adenocarcinoma.Translational lung cancer research · 2026Article
- Article
- Review
- Dissecting immunosuppressive microenvironment in chemotherapy-resistant colorectal cancer through single-cell transcriptomic analysis.Translational oncology · 2026Article
- Explainable machine learning and multimodal single cell analysis link NR4A2 to CD8Journal, genetic engineering & biotechnology · 2026Article
- Progenitor T cells drive chronic pulmonary type 2 inflammation.Nature immunology · 2026Article
- Applications of synthetic biology in biomedicine.Molecular biomedicine · 2026Review
- Paradoxical Th1 activation and CTLA-4 regulation is beneficial during latent cryptococcosis.mBio · 2026Article
- The transcription factor IRF8 drives tumor-specific exhaustion in CD8+ T cells.The Journal of experimental medicine · 2026Article
- Simultaneous TCR and IL-2 agonism selectively enhances epitope-specific CD8 T-cell responses during chronic viral infection.Journal of virology · 2026Article
- Human inherited RORγT deficiency encompasses genetic heterogeneity, T cell deficiency, and clinical homogeneity.medRxiv : the preprint server for health sciences · 2026Article
- Tumor infiltrating lymphocytes in glioblastoma: immunobiology and translational implications.NPJ precision oncology · 2026Review
- Atherosclerotic Cardiovascular Disease and Cancer.Immunological reviews · 2026Review
- CD8MedComm · 2026Review
- Cell-Type Deconvolution of Equine BALF RNA-Seq: A Critical Comparison with Matched Single-Cell Data.Genes · 2026Article
- New insights into progenitor exhausted T cell populations.Nature reviews. Immunology · 2026Article
538 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 8 institutions in 5 countries.
Funding
Abstract
Cytotoxic T cells are essential mediators of protective immunity to viral infection and malignant tumours and are a key target of immunotherapy approaches. However, prolonged exposure to cognate antigens often attenuates the effector capacity of T cells and limits their therapeutic potential
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.